Top Markets
Coin of the day
Cell Source, Inc. Cell Source, Inc.

Cell Source, Inc.

CLCS
Pozycja w akcjach #28218
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Cena akcji
$0.4
Ostatnia synchronizacja: 2026-10-02
Kapitalizacja rynkowa
$27.18M
Zmiana (1 dzień)
-14.88%
Zmiana (1 rok)
8.11%
Kraj
US
Handel Cell Source, Inc. (CLCS)

Kategoria

Historia stopy dywidendy dla Cell Source, Inc. (CLCS)
Stopa dywidendy (TTM) dla Cell Source, Inc. (symbol akcji: CLCS) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Cell Source, Inc. (CLCS) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji